flumazenil has been researched along with Local Neoplasm Recurrence in 2 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamada, N | 1 |
| Kuki, I | 1 |
| Hattori, T | 1 |
| Yamamoto, N | 1 |
| Nagase, S | 1 |
| Nukui, M | 1 |
| Inoue, T | 1 |
| Okazaki, S | 1 |
| Kawawaki, H | 1 |
| Horino, A | 1 |
| Sakuma, H | 1 |
| Horky, LL | 1 |
| Treves, ST | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flumazenil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
PET and SPECT in brain tumors and epilepsy.
Topics: Brain; Brain Neoplasms; Cell Proliferation; Dideoxynucleosides; Epilepsy; Flumazenil; Fluorodeoxyglu | 2011 |
1 other study available for flumazenil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Late relapse of anti-N-methyl-d-aspartate receptor encephalitis with amusia and transiently reduced uptake in
Topics: Adolescent; Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Female; Flumazenil; Humans; Iodi | 2022 |